| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Dmitry I. Gabrilovich | Q16729133 |
| P2093 | author name string | Indu Ramachandran | |
| Je-In Youn | |||
| Thomas Condamine | |||
| P2860 | cites work | Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein | Q24641894 |
| Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells | Q24658240 | ||
| How neutrophils kill microbes | Q24672245 | ||
| Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor | Q27320784 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis | Q28275735 | ||
| Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice | Q28385532 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis | Q28506334 | ||
| The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase | Q28507440 | ||
| Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 | ||
| Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment | Q30415763 | ||
| MIF: metastasis/MDSC-inducing factor? | Q30418662 | ||
| TGF-β signaling in myeloid cells is required for tumor metastasis | Q33355832 | ||
| Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer | Q33584851 | ||
| Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 | ||
| Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 | ||
| Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer | Q64378051 | ||
| SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion | Q64453691 | ||
| CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers | Q79674004 | ||
| Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells | Q80274418 | ||
| Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 | ||
| Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis | Q84595151 | ||
| Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. | Q33680309 | ||
| Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor | Q33805313 | ||
| Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells | Q33816455 | ||
| Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells | Q33873201 | ||
| Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells | Q33919954 | ||
| Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes | Q33978763 | ||
| Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. | Q33979918 | ||
| CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer | Q34043804 | ||
| Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. | Q34083483 | ||
| HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment | Q34243443 | ||
| Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes | Q34411361 | ||
| Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma | Q34600087 | ||
| S100A8/A9 activate key genes and pathways in colon tumor progression | Q34802977 | ||
| MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy | Q35028389 | ||
| Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. | Q35237477 | ||
| Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice | Q35370005 | ||
| Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice | Q35648172 | ||
| The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity | Q35750663 | ||
| Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment | Q35783465 | ||
| TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms | Q35814020 | ||
| Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma | Q36082220 | ||
| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 | ||
| Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 | ||
| Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells | Q36332711 | ||
| Myeloid derived suppressor cells in human diseases | Q36338349 | ||
| TNF signaling drives myeloid-derived suppressor cell accumulation | Q36357903 | ||
| Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung | Q36362003 | ||
| Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function | Q36384598 | ||
| Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis | Q36464443 | ||
| A CXCL1 paracrine network links cancer chemoresistance and metastasis | Q36482032 | ||
| Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer | Q36544980 | ||
| Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. | Q36625499 | ||
| Microenvironmental regulation of epithelial-mesenchymal transitions in cancer | Q36831337 | ||
| Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | Q36869774 | ||
| Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. | Q36902175 | ||
| HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion | Q37098976 | ||
| PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment | Q37193568 | ||
| Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis | Q37200858 | ||
| Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. | Q37317912 | ||
| CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis | Q37591247 | ||
| A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model | Q37691064 | ||
| Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients | Q37704869 | ||
| Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. | Q37714611 | ||
| Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function | Q37808561 | ||
| On the armament and appearances of human myeloid-derived suppressor cells | Q38031742 | ||
| History of myeloid-derived suppressor cells | Q38141522 | ||
| Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer | Q39188755 | ||
| Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. | Q39244686 | ||
| Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. | Q39321728 | ||
| Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy. | Q39328708 | ||
| Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition | Q39405423 | ||
| Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells | Q39584588 | ||
| Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. | Q39876429 | ||
| Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. | Q39997114 | ||
| Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity | Q40013431 | ||
| Bv8 regulates myeloid-cell-dependent tumour angiogenesis | Q40038500 | ||
| Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. | Q40100311 | ||
| CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells | Q40259796 | ||
| Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. | Q40605195 | ||
| Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. | Q42183046 | ||
| Regulation of T cell receptor CD3zeta chain expression by L-arginine | Q43957769 | ||
| Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Q44017442 | ||
| Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins | Q45171571 | ||
| Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. | Q45925410 | ||
| Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. | Q45936373 | ||
| Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties | Q46064310 | ||
| Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion | Q46440292 | ||
| Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. | Q50909590 | ||
| Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. | Q54421148 | ||
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host | Q57054792 | ||
| Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis | Q59276609 | ||
| Mycobacterium bovis Bacillus Calmette-Guérin Vaccination Mobilizes Innate Myeloid-Derived Suppressor Cells Restraining In Vivo T Cell Priming via IL-1R–Dependent Nitric Oxide Production | Q59807735 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tumor metastasis | Q120912381 |
| P304 | page(s) | 97-110 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Annual Review of Medicine | Q567363 |
| P1476 | title | Regulation of tumor metastasis by myeloid-derived suppressor cells | |
| P478 | volume | 66 |
| Q89239787 | 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS |
| Q48295124 | 4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells |
| Q92465156 | A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b |
| Q58773898 | Abscopal effect of radiotherapy combined with immune checkpoint inhibitors |
| Q37178335 | Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape |
| Q92703407 | Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment |
| Q47381391 | Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity |
| Q36665783 | Arresting supporters: targeting neutrophils in metastasis. |
| Q45813459 | Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients |
| Q92757487 | Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences |
| Q47281990 | Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. |
| Q60489257 | Cancer immunoediting and resistance to T cell-based immunotherapy |
| Q52313106 | Canonical NF-κB signaling in myeloid cells promotes lung metastasis in a mouse breast cancer model. |
| Q40718867 | Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy |
| Q98906904 | Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis |
| Q40348056 | Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation |
| Q60931267 | Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization |
| Q33876637 | Chemotherapy and tumor microenvironment of pancreatic cancer. |
| Q92839413 | Clinical biocharacterization of immunophenotype in hepatocellular carcinoma patients |
| Q40099659 | Deep Immune Profiling of an Arginine-Enriched Nutritional Intervention in Patients Undergoing Surgery |
| Q42368949 | Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine |
| Q59789321 | Dexmedetomidine expands monocytic myeloid-derived suppressor cells and promotes tumour metastasis after lung cancer surgery |
| Q37559326 | Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy |
| Q60949810 | Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies? |
| Q58129606 | Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis |
| Q28821976 | Endothelial cell-derived CD95 ligand serves as a chemokine in induction of neutrophil slow rolling and adhesion |
| Q91826260 | Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells |
| Q38963271 | Epigenetic Component p66a Modulates Myeloid-Derived Suppressor Cells by Modifying STAT3. |
| Q39110788 | Every exercise bout matters: linking systemic exercise responses to breast cancer control. |
| Q47418274 | Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells |
| Q33641799 | Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis |
| Q94571010 | Expansion of Myeloid-Derived Suppressor Cells Correlates with Renal Progression in Type 2 Diabetic Nephropathy |
| Q36983860 | FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). |
| Q36547291 | G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers |
| Q49876679 | Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice |
| Q57106917 | Genetics and biology of prostate cancer |
| Q93136814 | Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients |
| Q52839182 | High granulocytic myeloid-derived suppressor cell levels in the peripheral blood predict a better IVF treatment outcome. |
| Q57138348 | IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors |
| Q39613201 | IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer |
| Q93023944 | Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs |
| Q38840291 | Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. |
| Q55457222 | Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. |
| Q56872957 | Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice |
| Q48949605 | Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer |
| Q92856193 | LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression |
| Q33564156 | Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. |
| Q38671001 | MOLECULAR PATHWAYS: TARGETING THE MICROENVIRONMENT OF LIVER METASTASES. |
| Q90196428 | MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells |
| Q92826809 | MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices |
| Q47137850 | Manipulation of Innate Immunity for Cancer Therapy in Dogs. |
| Q98771234 | Mechanisms of Cancer Resistance to Immunotherapy |
| Q90526088 | Metastatic niche functions and therapeutic opportunities |
| Q37520262 | Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases |
| Q89097040 | Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis |
| Q37403508 | MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma |
| Q33653403 | Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. |
| Q47550777 | Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections. |
| Q37741335 | Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade |
| Q89952894 | Mycobacterium tuberculosis and myeloid-derived suppressor cells: Insights into caveolin rich lipid rafts |
| Q26801832 | Myeloid Cells as Targets for Therapy in Solid Tumors |
| Q64102304 | Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression |
| Q92650141 | Myeloid-Derived Suppressor Cells Are Regulated by Estradiol and Are a Predictive Marker for IVF Outcome |
| Q38528814 | Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer |
| Q89976160 | Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer |
| Q38931895 | Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon? |
| Q48293607 | Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment |
| Q41552935 | Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. |
| Q98280908 | Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas |
| Q39331381 | Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. |
| Q38702891 | Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. |
| Q92627552 | Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance |
| Q28069360 | Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy |
| Q47563950 | Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells |
| Q51163749 | Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2-dependent angiogenesis in mice. |
| Q36428411 | Neutrophils support lung colonization of metastasis-initiating breast cancer cells |
| Q89583558 | Novel tumour antigens and the development of optimal vaccine design |
| Q26777205 | Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate |
| Q90720156 | Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent |
| Q91106316 | Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells |
| Q55511990 | Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy. |
| Q88081063 | Plasticity of myeloid-derived suppressor cells in cancer |
| Q91711825 | Potential Role of Myeloid-Derived Suppressor Cells (MDSCs) in Age-Related Macular Degeneration (AMD) |
| Q40717214 | Primary Heligmosomoides polygyrus bakeri infection induces myeloid-derived suppressor cells that suppress CD4+ Th2 responses and promote chronic infection |
| Q55020408 | Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. |
| Q36345203 | ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells |
| Q39017268 | Radiotherapy and immunotherapy: a beneficial liaison? |
| Q37012718 | Rapid dissemination of RET-transgene-driven melanoma in the presence of non-obese diabetic alleles: Critical roles of Dectin-1 and Nitric-oxide synthase type 2. |
| Q96945923 | Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy |
| Q47773956 | Revisiting ovarian cancer microenvironment: a friend or a foe? |
| Q40619105 | Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells |
| Q39103948 | Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. |
| Q38731474 | Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma. |
| Q38740336 | Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo. |
| Q90176829 | Stroke Exacerbates Cancer Progression by Upregulating LCN2 in PMN-MDSC |
| Q92441945 | Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer |
| Q37725564 | Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer |
| Q93060376 | Surgical stress and cancer progression: the twisted tango |
| Q28075605 | TGFΒ-induced transcription in cancer |
| Q50924516 | TNFα-induced M-MDSCs promote transplant immune tolerance via nitric oxide. |
| Q58601568 | Tarin stimulates granulocyte growth in bone marrow cell cultures and minimizes immunosuppression by cyclo-phosphamide in mice |
| Q39000116 | The Diverse Biological Functions of Neutrophils, Beyond the Defense Against Infections |
| Q90601904 | The Effect of Immunosuppressive Drugs on MDSCs in Transplantation |
| Q90056672 | The Engagement Between MDSCs and Metastases: Partners in Crime |
| Q28388630 | The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment |
| Q39169603 | The Unique Molecular and Cellular Microenvironment of Ovarian Cancer |
| Q37381494 | The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer |
| Q36072831 | The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth |
| Q38610872 | The contribution of tumour-derived exosomes to the hallmarks of cancer |
| Q92757933 | The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression |
| Q53106855 | The effect of immunosuppressive drug cyclosporine A on myeloid-derived suppressor cells in transplanted mice. |
| Q38649547 | The immunobiology of myeloid-derived suppressor cells in cancer |
| Q98177248 | The immunology of renal cell carcinoma |
| Q48325267 | Therapeutic blockade of Foxp3 in experimental breast cancer models. |
| Q50988785 | Therapeutic cancer vaccines. |
| Q64897803 | Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. |
| Q38734237 | Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis |
| Q36322351 | Transcriptional regulation of myeloid-derived suppressor cells |
| Q55222132 | Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer. |
| Q50104130 | Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies |
| Q92787500 | Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment |
| Q90468512 | Tumour devascularisation as a potential immunotherapeutic strategy |
| Q38998166 | Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. |
| Q57464770 | Unique pattern of neutrophil migration and function during tumor progression |
| Q90169732 | Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer |
| Q57181187 | ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer |
| Q90364630 | β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells |
Search more.